IVUS Use during Left Main PCI improve Immediate and Long Term Outcome Where is the Evidence? E Murat Tuzcu, MD, FACC Professor of Medicine Vice Chairman.

Slides:



Advertisements
Similar presentations
MAIN-COMPARE Study – Disclosure Information
Advertisements

MAIN-COMPARE Study Stents versus Coronary-Artery Bypass Grafting for Left Main Coronary Artery Disease.
TAVOLA ROTONDA Quale Ruolo Clinico e Quale Rimborso per la Franctional Flow Reserve? Correlazioni anatomo-funzionali FFR vs IVUS Luigi Vignali, Parma Bologna.
Introduction Recent guidelines considered PCI to be a potential alternative to CABG for ULMCA stenosis, based on several large registries and randomized.
Comparison of the New Mayo Clinic Risk Scores and Clinical SYNTAX Score in Predicting Adverse Cardiovascular Outcomes following Percutaneous Coronary Intervention.
Professor Abdus Samad MD FACC Karachi Institute of Heart Diseases Karachi, Pakistan May 1, 2010.
Francesco Burzotta HOTLINE III, ESC Congress 2007 September 4th 2007, Vienna OPTIMIST: the Outcome of Pci for stent-ThrombosIs MultIcentre STudy Institute.
Journal : Evidence Review PCI : Role of FFR Dr Binjo J Vazhappilly SR Cardiology MCH Calicut.
Left Main Coronary Artery Dissection Complicating Diagnostic Coronary Angiography Layth A. Mimish MBChB, FRCPC, FACC Medical Director The Cardiovascular.
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli,
STEMI Due to Stent Thrombosis: An Enlarging Subgroup of High Risk Patients Bruce Brodie, Adam Bensimhon, Nathan Fleishman, Charles Hansen, Mike Cooper,
Seung-Jung Park, MD, PhD On behalf of the PRECOMBAT Investigators Professor of Medicine, University of Ulsan College of Medicine, Heart Institute, Asan.
Chaim Lotan MD, Yaron Almagor MD, Karel Kuiper MD, M.J. Suttorp MD, William Wijns MD The SICTO Study CYPHER TM Sirolimus-eluting stent in Chronic Total.
1 1 The Use of Percutaneous Coronary Intervention in Patients with Class I Indications for Coronary Artery Bypass Graft Surgery: Data from the National.
Murat Sezer, Emre Aslanger, Arif Cimen, Ebru Yormaz, Cuneyt Turkmen, Berrin Umman, Yılmaz Nisanci, Zehra Bugra and Sabahattin Umman Istanbul University,
Tarunjit Singh Department of Internal Medicine Westchester Medical Center New York Medical College Valhalla NY.
Two-Year Clinical Outcomes Yan Li MD., PhD. On behalf of FIREMAN Investigators Associated Professor of Department of Cardiology of Xijing Hospital Fourth.
Long Term Clinical Outcomes Following Drug-Eluting and Bare Metal Stenting in Massachusetts Laura Mauri, MD, MSc; Treacy Silverstein, B.Sc.; Ann Lovett,
Revascularizaton of Ischemic DCM Percutaneous Revascularization and Hemodynamic Support Matthew R. Wolff, M.D. University of Wisconsin Disclosures: Cordis.
Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease.
Predictive Value of Coronary Calcium Scoring Matthew Budoff, MD, FACC, FAHA Associate Professor of Medicine UCLA School of Medicine Director, Cardiac CT.
SIROLIMUS-ELUTING STENTS EFFECTIVELY INHIBIT NEOINTIMAL PROLIFERATION AS COMPARED TO BARE METAL STENTS IN DISEASED SAPHENOUS VEIN GRAFTS: 6-month IVUS.
Left Main Stem Intervention Trials & Registries Keith D. Dawkins MD FRCP FACC Southampton University Hospital UK.
LM strategy Interventional cardiology dpt Cardiovascular Hospital - Lyon - France Gilles Rioufol MD PhD INSERM U1060 High Tech Marseille, 26 Janvier 2012.
左主干分叉病变治疗策略的选择 Left main bifurcation: what is the best choice? Lei Ge, MD Department of Cardiology, Zhongshan Hospital, Fudan University.
Samsung Medical Center Cardiac & Vascular Center Young Bin Song, Joo-Yong Hahn, Seung-Hyuk Choi, Jin-Ho Choi, Sang Hoon Lee, Myung-Ho Jeong, Hyo-Soo Kim,
LONG-TERM OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE: INITIAL CLINICAL EXPERIENCE. Graidis Ch. 1,
6/9/2008 Comparative effectiveness reviews: methodological observations David B. Matchar, MD Professor of Medicine and Director, Center for Clinical Health.
Direct Stenting is Better (Debate Session) 동아의대 김 무 현.
Baseline Characteristics of the Patient Population (n=525) Colin Berry, et al. Circulation 2007;115:
Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?
Is the Decision-Making after Failure of CTO Angioplasty Same? Infarct Related CTO or Non- Infarct Related CTO (Continue the Procedure in Other Vessel or.
左主干病变 PCI 中 IVUS 的指导 作用:是否必需? 钱杰阜外心血管病医院. 术前评价 LM 病变.
Clinical Experience with the Bio Active Stent (BAS) in FINLAND 9 e CFCI Hotel Meridien Etoile Paris, France 10 Octobre 2007 Pasi Karjalainen, MD, PhD.
Lianglong Chen MD PhD FACC
Endeavor 4: A Randomized Comparison of a Zotarolimus- Eluting Stent and a Paclitaxel- Eluting Stent in Patients with Coronary Artery Disease Martin B.
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.
ISAR-CABG Objective To compare the efficacy of DES with BMS in a randomized trial powered for clinical events Sample 610 patients with de novo SVG lesions.
Saqib Chowdhary Wythenshawe Hospital STENT THROMBOSIS How Do IVUS & OCT Help.
Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Prospective Application of Pre-Defined Intravascular.
Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.
Left Main PCI: What is Best Practice? Ayman A. Magd, MD FSCAI Board of Trustees of SCAI Board of Trustees of SCAI Professor of Cardiology, Azhar University.
4 th European Bifurcation Club September PRAGUE A comprehensive meta- analysis on drug-eluting stenting for unprotected left main disease.
Columbia University Medical Center Cardiovascular Research Foundation New York City, NY Akiko Maehara, MD Use of IVUS Reduces Stent Thrombosis and Myocardial.
Left Main PCI: What is Best Practice? Theodore A Bass, MD FSCAI, FACC President-Elect SCAI Professor of Medicine, University of Florida Medical Director.
Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE
Intravascular ultrasound (IVUS) in percutaneous coronary intervention – summary of key articles While angiography is routinely used for assessment of CAD,
Intravascular ultrasound (IVUS) in the treatment of long and diffuse lesions– summary of key articles Prepared by Radcliffe Cardiology 21 November2016.
Intravascular ultrasound (IVUS) in percutaneous coronary interventions – summary of key articles While angiography is routinely used for assessment of.
Clinical Usefulness of Post-Stenting FFR
The MASS-DAC Study.
When IVUS? When FFR? Assessing Intermediate Lesions
Debate: What Does the Future Hold for the Treatment of Unprotected Left Main Disease? More PCI No More Routine Surgery Ron Waksman, MD, FACC Washington.
Overview of the Clinical Utility of IVUS to Optimize PCI
OCT-Guided PCI What needs to be done to establish criteria?
The Guidelines Should Be Change!
The Hidden Cost of Underutilizing PCI for Chronic Total Occlusions
Giuseppe Biondi Zoccai, MD
Left Main PCI: What is Best Practice?
AN INTERNATIONAL COLLABORATIVE META-ANALYSIS ON 1,274 PATIENTS UNDERGOING PERCUTANEOUS DRUG-ELUTING STENTING FOR UNPROTECTED LEFT MAIN CORONARY ARTERY.
Significance of Periprocedural Myocardial Infarctions in Percutaneous Coronary Interventions A New Look at an Old Topic Abhiram Prasad, MD, FRCP, FESC,
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
Maintenance of Long-Term Clinical Benefit with
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
MACE: Death, MI or TLR at 5 years
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.
Glenn N. Levine et al. JACC 2011;58:e44-e122
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
Presentation transcript:

IVUS Use during Left Main PCI improve Immediate and Long Term Outcome Where is the Evidence? E Murat Tuzcu, MD, FACC Professor of Medicine Vice Chairman Department of Cardiovascular Medicine Cleveland Clinic

Does IVUS improve PCI Outcomes StudyHelpfulNo SIPSX CRUISEX Choi et alX AVIDX CENICX Gaster et alX RESISTX TULIPX OPTICUSX

Role of IVUS in Stenting in the DES Era Intravascular IVUS-guided DES Placement Associated with Reduced Incidence of Recurrent Clinical Events B. Claessen et al., JACC 2010;56: pts, IVUS guidance in 632 (42%), F/U 2 yrs CRF and Amsterdam Multivariate Analysis for Predicting Death/MI IVUS guidance Age CHF Renal impairment Time in Years P=0.004 Non IVUS Cohort IVUS Cohort

Park SJ et al., JACC 2005;45: Comparison of BMS (IVUS 75%) and DES (IVUS 86%) MACE Free Survival (%) Months SES group BMS group 81.4 ± 3.7% 98.0 ± 1.4% IVUS in LMCA Stenting

Event-free Survival (%) Time (days) Distal LM Non-Distal LM IVUS (n=14) No IVUS (n=12) No IVUS (n=22) IVUS (n=10) Agostoni et al AJC 2005;95:644-7 IVUS Guidance in DES for LMCA Stenosis Event Free Survival in 24 IVUS+ and 34 IVUS- Patients

975 elective BMS or DES for unprotected LMCA stenosis975 elective BMS or DES for unprotected LMCA stenosis IVUS (756), angiography (219) guidance by operator discretionIVUS (756), angiography (219) guidance by operator discretion Angiography group was older and sickerAngiography group was older and sicker 201 propensity-score matching pairs (DES + BMS)201 propensity-score matching pairs (DES + BMS) 145 propensity-score matching pairs of DES patients145 propensity-score matching pairs of DES patients MAIN COMPARE REGISTRY

Park SJ Circ Cardiovasc Interv 2009;2: DeathDeath or MI Patients at risk IVUS-guidance Angiography-guidance Angiography-guidance IVUS-guidance P= % ( %) 6.0% ( %) Cumulative Mortality (%) Days Patients at risk IVUS-guidance Angiography-guidance Angiography-guidance IVUS-guidance P= % ( %) 22.7% ( %) Cumulative Incidence of Death or MI (%) Days IVUS Guidance in Stenting for LMCA Stenosis 3 year death and MI (K-M) in 201 propensity matched pairs

Park SJ Circ Cardiovasc Interv 2009;2: TVRDeath/MI/TVR Patients at risk IVUS-guidance Angiography-guidance Angiography-guidance IVUS-guidance P= % ( %) 8.8% ( %) Cumulative Incidence of TVR (%) Days Patients at risk IVUS-guidance Angiography-guidance P= Cumulative Incidence of Death, MI or TVR (%) Months Angiography-guidance IVUS-guidance 28.0% 22.2% IVUS Guidance in DES for LMCA Stenosis 3 year TVR and MACE (K-M) in 201 propensity matched pairs

IVUS Guidance in DES for LMCA Stenosis Cumulative Mortality (%) Patients at risk IVUS-guidance Angiography-guidance Months % 16.0% P=0.048 Angiography-guidance IVUS-guidance 3 year mortality (K-M) in 145 propensity matched pairs

Differences in Patient Outcomes for LMCA PCI Thoraxcenter vs. Asan Medical Center: Impact of Baseline Characteristics on Outcomes of DES Age 65, LVEF 45% Euroscore 4.3, IVUS 32%, SYNTAX score 39 STEMI 23%, Shock 9% Age 61, LVEF 59% Euroscore 3.3, IVUS 89% 32%, SYNTAX score 39 STEMI 0%, Shock 0% All Cause Mortality 35% versus, 6% Onuma et al. JACC Int, 2010Park DW et al., JACC, 2010

Left Main Coronary Artery (LMCA) Disease T o treat or not to treat? That is the question.

IVUS and Left Main Disease IVUS MLD (mm) QCA MLD (mm) r= IVUS ref (mm) QCA Ref. (mm) r=0.495 Independent predictors of MACE DM (P=0.004) Any untreated lesion >50% (p=0.04) IVUS MLD (P=0.005) IVUS DS QCA DS p=0.106 AS Abizaid et al JACC 1999;34: MACE IVUS MLD (mm) DM and  1 untreated vessel with DS  50% DM and no untreated vessels No DM and  1 untreated vessel with DS  50% No DM and no untreated vessels 122 patients with moderate LMCA disease, f/u 1 year

Assessment of Intermediate LMCA Lesions by IVUS 354 Patients MLA ≥6.0 mm 2 (N=186) MLA <6.0 mm 2 (N=168) 7 revascularized16 not revascularized No LMCA revascularization (n=179, 96%) LMCA revascularization (n=152, 90%) 56% PCI of other vessels 55% CABG 45% PCI (+ other vessels in 62%) LITRO Study – 22 Spanish Centers De La Torre Hernandez et al. ACCi2 2010

Survival free of cardiac death, MI and any revascularization P=0.22 Defer (n=179) Revascularization (n=152) Survival free of cardiac death P=0.20DeferRevascularization De La Torre Hernandez et al. ACCi Assessment of Intermediate LMCA Lesions by IVUS Survival in Revascularized and Deferred Patients

Time Defer (medical therapy) with MLA ≥6mm 2 (n=179) Survival free of Cardiac Death P= Defer (medical therapy) with MLA <6mm 2 (n=160) Assessment of Intermediate LMCA Lesions by IVUS LITRO Study – Survival in Medically Treated Patients De La Torre Hernandez et al. ACCi2 2010

The Assessment of LMCA Shortfalls of Luminology for Even Experienced Clinicians

Agreement or Disagreement on Stenosis Severity Visual Assessment%(absolute #) Reviewer Anscorrect 53%27/51 sincorrect22%11/51 uunsure25%13/51 Reviewer Bnscorrect49%25/51 sincorrect39%20/51 uunsure12%6/51 Reviewer Cnscorrect51%26/51 sincorrect49%25/51 uunsure-0/51 Reviewer Cnscorrect45%23/51 sincorrect33%17/51 uunsure22%11/51 Lindstaedt M et al. Int J Cardiol. 2007;120(2): Reviewer Assessment Results 51 intermediate LMT assessed by angiography and FFR 4 experienced interventional cardiologist correctly classified lesion severity in 50% of patients. 4 experienced interventional cardiologist correctly classified lesion severity in 50% of patients. Interobserver variability was large resulting in unanimous correct classification in only 29% Interobserver variability was large resulting in unanimous correct classification in only 29%

The Grey Zone of FFR De Bruyne B et al. Circulation 2001;104: FFR Sensitivity Specificity FFR = 0.75 Specificity Sensitivity 0.80 FFR Caveats Other coronary stenosis Other coronary stenosis Distal LMCA stenosis Distal LMCA stenosis Variability of hyperemic response Variability of hyperemic response

IVUS shows us so much more! Courtesy of G Mintz (modified) Vessel size Vessel size Remodeling Remodeling Length Length Calcification Calcification Ostium Ostium Bifurcation Bifurcation

Morphological Assessment of LMCA by IVUS Maehara A et al., AJC 2001;88:1-4 OstiumBifurcationp value n=32n=55 Plaque burden (%)62 ± 1580 ± 9< Max Calcium Arc (°)78 ± ± 101< Eccentric plaque (%) Lesion length (mm)2.3 ± ± Remodeling index0.87 ± ± Bifurcation vs Ostium: more calcium and plaque, longer, and more positive remodeling Distribution of atherosclerosis in LMCA: Ostium vs Bifurcation

0% 100% Medina 1,1,1 (n=21) Medina 1,1,0 (n=9) Medina 1,0,1 (n=6) Medina 0,1,1 (n=11) Medina 1,0,0 (n=7) Medina 0,1,0 (n=14) Medina 0,0,1 (n=12) Medina 0,0,0 (n=60) All lesions (n=80) Others Oviedo et al. Circ Cardiovasc Interv. 2010;3:105-12

Impact of IVUS on TVR after LMCA Stenting Kang SJ et al., 2011;107: patients with distal LMCA stenosis w/ 42 mo F/U Pre-PCI MLA at POC was predictor of MACE. Pre-PCI MLA at POC was predictor of MACE. MLA at POC determined final stent size MLA at POC determined final stent size POC: Polygon of confluance

Ostial Left Main Stenosis

A B A B

Why IVUS is Important in LMCA Intervention IVUS improves our understanding of the pathology better and helps to plan the strategy of PCIIVUS improves our understanding of the pathology better and helps to plan the strategy of PCI Determination of the extent and distribution of atheroma in distal LMT, ostial LAD and Cx Determination of the extent and distribution of atheroma in distal LMT, ostial LAD and Cx Location and involvement of the ostium of LMCALocation and involvement of the ostium of LMCA True vessel size of LMCATrue vessel size of LMCA True vessel size of LAD and CxTrue vessel size of LAD and Cx Optimize stent expansion particularly at the osteaOptimize stent expansion particularly at the ostea Ensure coverage of the LMCA-ostium when necessaryEnsure coverage of the LMCA-ostium when necessary Identify and treat complicationsIdentify and treat complications